Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00726453 · ClinicalTrials.gov registry record · NA
The Medtronic RESOLUTE US Clinical Trial
A NA study, sponsored by Medtronic Vascular.
- Completed
- Registry status
- NA
- Development phase
- 1,516
- Enrollment target
NCT00726453 is a NA study that has completed, run by Medtronic Vascular. The registered enrollment target is 1,516 participants.
The verdict
NCT00726453, a NA study, has completed, sponsored by Medtronic Vascular.
- COMPLETED
- Registry status
- NA
- Development phase
- 1,516 participants
- Enrollment target
Study Summary
The objective of the study is to assess the safety and effectiveness of the Resolute Zotarolimus-Eluting Coronary Stent System for the treatment of de novo lesions in native coronary arteries with a reference vessel diameter (RVD) of 2.25 mm to 4.2 mm.
Interventions
- DEVICE Resolute Zotarolimus-Eluting Coronary Stent
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,516 participants |
| Start Date | 2008-07 |
| Est. Completion | 2016-03 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00726453
The ClinicalTrials.gov registry entry for NCT00726453 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 1,516 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Medtronic Vascular, which has 26 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Resolute Zotarolimus-Eluting Coronary Stent is the first listed.
NCT00726453 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00726453 about?
NCT00726453 is a clinical study titled "The Medtronic RESOLUTE US Clinical Trial". The objective of the study is to assess the safety and effectiveness of the Resolute Zotarolimus-Eluting Coronary Stent System for the treatment of de novo lesions in native coronary arteries with a reference vessel diameter (RVD) of 2.25 mm to 4.2 mm.
What is the current status of trial NCT00726453?
This trial is currently completed. It is a NA study. The enrollment target is 1,516 participants. The study started on 2008-07. Estimated completion is 2016-03.
What interventions are being tested in trial NCT00726453?
The interventions under investigation include: Resolute Zotarolimus-Eluting Coronary Stent (DEVICE).
Who is sponsoring clinical trial NCT00726453?
This trial is sponsored by Medtronic Vascular, which has 26 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.